Forward-Looking Statements
This presentation contains “forward-looking statements” under the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Graybug’s and CalciMedica’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained in this presentation include, but are not limited to, statements about: Graybug’s and CalciMedica’s expectations with respect to future performance and anticipated financial impacts of the proposed transaction, the satisfaction of closing conditions to the proposed transaction and the timing of the completion of the proposed transaction. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside Graybug’s and CalciMedica’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the outcome of any legal proceedings that may be instituted against Graybug or CalciMedica following the announcement of the proposed transaction; the inability to complete the proposed transaction, including due to the inability to concurrently close the merger and the private placement of common stock or due to failure to obtain approval of the stockholders of Graybug; delays in obtaining, adverse conditions contained in, or the inability to obtain necessary regulatory approvals or complete regular reviews required to complete the proposed transaction; the ability of Graybug to remain listed on the Nasdaq stock market; the inability to recognize the anticipated benefits of the proposed transaction, which may be affected by, among other things, competition, the ability of the combined company to grow and successfully execute on its business plan; costs related to the proposed transaction; changes in the applicable laws or regulations; the possibility that the combined company may be adversely affected by other economic, business, and/or competitive factors; the impact of the global COVID-19 pandemic; and other risks and uncertainties indicated from time to time described in Graybug’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, the proxy statement, once available, relating to the proposed transaction, including those under “Risk Factors” therein, and in Graybug’s other filings with the U.S. Securities and Exchange Commission (the “SEC”). Graybug and CalciMedica caution that the foregoing list of factors is not exclusive, and not to place undue reliance upon any forward-looking statements, including projections, which speak only as of the date made. Moreover, Graybug and CalciMedica operate in a very competitive and rapidly changing environment. New risks emerge from time to time. Except as required by law, neither Graybug nor CalciMedica undertakes any obligation to update publicly any forward-looking statements for any reason after the date of this presentation, whether to conform these statements to actual results or to changes in their expectations.
Important Additional Information
In connection with the merger, Graybug intends to file with the SEC preliminary and definitive proxy statements relating to the proposed merger and any other relevant documents. The definitive proxy statement will be mailed to Graybug’s stockholders determined as of a record date, which is to be established for voting on the proposed merger and any other matters to be voted on at the special meeting. Before making any voting decision, Investors and security holders are urged to read the preliminary and definitive proxy statements, any amendments or supplements thereto, and any other documents to be filed with the SEC in connection with the proposed merger or incorporated by reference in the proxy statements when they become available because they will contain important information about Graybug, CalciMedica and the proposed merger. Investors and security holders may obtain free copies of these documents (when they are available) on the SEC’s web site at www.sec.gov, on Graybug’s website at https://investors.graybug.vision/ or by contacting Graybug’s Investor Relations via email at IR@graybug.vision or by telephone at (650) 487-2409.